Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Day 36 Assessments Clear all
Suspended Phase 1 Interventional

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161
View directory record Official record
Conditions
Ovarian Tumors
Interventions
GRN-300, Paclitaxel
Drug
Lead sponsor
Green3Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Not applicable Interventional

Investigating KardioPAC Mobile App to Improve Physical Fitness Among Cardiac Rehabilitation Patients

NCT05643976
View directory record Official record
Conditions
Cardiac Rehabilitation, Exercise, Quality of Life
Interventions
KardioPAC Mobile Application, Standard of Care
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 3, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885
View directory record Official record
Conditions
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions
Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
662
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

NCT04669158
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis, Fibrosis
Interventions
Idebenone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

NCT01446458
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
Interventions
Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02558140
View directory record Official record
Conditions
Neoplasms
Interventions
RO6874813
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced Melanoma

NCT00705640
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy
Biological · Procedure
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Alternatives for Reducing Chorea in Huntington Disease

NCT01897896
View directory record Official record
Conditions
Chorea Associated With Huntington Disease
Interventions
SD-809
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies

NCT00921739
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
Interventions
Esophageal sparing IMRT
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Adjuvant Radiation Therapy, Docetaxel, Cisplatin
Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 3, 2026, 8:08 PM EDT
Completed No phase listed Observational

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

NCT06746051
View directory record Official record
Conditions
RSV Infections
Interventions
Not listed
Lead sponsor
Shionogi
Industry
Eligibility
Up to 36 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Syracuse, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

NCT02281955
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 2 Interventional

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

NCT03361410
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 3, 2026, 8:08 PM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Astigmatic Contact Lenses

NCT03086447
View directory record Official record
Conditions
Visual Acuity
Interventions
Investigational Contact Lens, Marketed Contact Lens
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
17
States / cities
Whittier, California • Jacksonville, Florida • Jacksonville Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 3, 2026, 8:08 PM EDT
Not yet recruiting Not applicable Interventional

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

NCT07842341
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions
Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group)
Behavioral
Lead sponsor
Texas Southern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 3, 2026, 8:08 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

NCT04547777
View directory record Official record
Conditions
Glioma, Malignant
Interventions
D2C7-IT, 2141-V11
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 1 Interventional

A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment

NCT01966328
View directory record Official record
Conditions
Vitreomacular Attachment, Vitreomacular Traction, Vitreomacular Adhesion
Interventions
36% Resolvine Intravitreal Injection, 9% Resolvine Intravitreal Injection
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 3, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

NCT00256750
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 3, 2026, 8:08 PM EDT
Suspended Phase 2 Interventional

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04519879
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Duarte, California • Glendora, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 3, 2026, 8:08 PM EDT
Terminated Not applicable Interventional Results available

The Effect of AposTherapy on Knee Pain

NCT03171168
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain
Interventions
AposTherapy, Traditional Physical Therapy
Device · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 3, 2026, 8:08 PM EDT
Recruiting Not applicable Interventional

Telerehabilitation In The Home After Stroke

NCT06682429
View directory record Official record
Conditions
Stroke
Interventions
Telerehabilitation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
27
States / cities
Downey, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 3, 2026, 8:08 PM EDT